Fibroblast Growth Factor 23 as a Therapeutic Target

Authors

  • Fan Li, MD, MS
  • Zhousheng Xiao, MD, PhD

Keywords:

antagonist, fibroblast

Abstract

This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease
conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibroblast growth factor receptors
(FGFR) tyrosine kinase inhibitor, FGF-23 antibody, FGF-23 C-terminal peptide, CYP24A1 inhibitor, and FGF-23 antagonist. We
also update the advantages and disadvantages of targeting upstream and downstream molecules in FGF-23 signaling pathways.

Downloads

Published

2018-10-29

How to Cite

Fan Li, MD, MS, & Zhousheng Xiao, MD, PhD. (2018). Fibroblast Growth Factor 23 as a Therapeutic Target. Nephrology, 16–21. Retrieved from https://openventio.us/index.php/NOJ/article/view/2253

Issue

Volume 4 Issue 1 2018

Section

Articles

License

All content published in Nephrology – Open Journal (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.

Most read articles by the same author(s)